Allogeneic T cell progenitors, cultured ex-vivo

BIOLOGICAL2 trials

Sponsors

Smart Immune SAS

Conditions

Hematological Malignancies

Phase 1

Safety and Efficacy of SMART101 in Pediatric and Adult Patients With Hematological Malignancies After T Cell Depleted Allo-HSCT

RecruitingNCT04959903

Smart Immune SASHematological Malignancies

Start: 2022-03-31End: 2027-05-31Target: 36Updated: 2023-03-06

Safety and Efficacy of SMART101 in Adult Patients With Hematological Malignancies After Haploidentical HSCT With Post-transplant Cyclophosphamide

RecruitingNCT05768035

Smart Immune SASHematological Malignancies

Start: 2023-06-06End: 2026-07-31Target: 40Updated: 2023-09-25

Related Papers

SMART101 Donor T-Lymphoid Progenitors to Accelerate Immune Reconstitution Post HLA Mismatched Peripheral Blood Stem Cell Transplantation with Post-Transplant Cyclophosphamide: Reset-02 First-in-Human Phase I/II

Blood2024-11-051 citations

P1403: SI101-01 PHASE I/II STUDY EVALUATING SAFETY AND EFFICACY OF ALLOGENEIC SMART101 T-LYMPHOID PROGENITOR INJECTION TO ACCELERATE IMMUNE RECONSTITUTION AFTER T-CELL DEPLETED ALLOGENEIC HSCT

HemaSphere2023-08-01